$2.46T
Total marketcap
$205.41B
Total volume
BTC 50.07%     ETH 15.65%
Dominance

Revance Therapeutics RVNC Stock

4.94 USD {{ price }} -6.880298% {{change_pct}}%
Exchange
NasdaqGM
Market Cap
514.82M USD
LOW - HIGH [24H]
4.88 - 5.35 USD
VOLUME [24H]
2.84M USD
{{ volume }}
P/E Ratio
0
Earnings per share
-3.83 USD

Revance Therapeutics Price Chart

Revance Therapeutics RVNC Financial and Trading Overview

Revance Therapeutics stock price 4.94 USD
Previous Close 28.45 USD
Open 28.24 USD
Bid 0 USD x 800
Ask 0 USD x 1200
Day's Range 27.91 - 28.97 USD
52 Week Range 12.34 - 37.98 USD
Volume 1.46M USD
Avg. Volume 1.27M USD
Market Cap 2.41B USD
Beta (5Y Monthly) 0.843661
PE Ratio (TTM) N/A
EPS (TTM) -3.83 USD
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 40.45 USD

RVNC Valuation Measures

Enterprise Value 2.55B USD
Trailing P/E N/A
Forward P/E -21.578947
PEG Ratio (5 yr expected) -0.78
Price/Sales (ttm) 15.398599
Price/Book (mrq) N/A
Enterprise Value/Revenue 16.297
Enterprise Value/EBITDA -11.216

Trading Information

Revance Therapeutics Stock Price History

Beta (5Y Monthly) 0.843661
52-Week Change 122.30%
S&P500 52-Week Change 20.43%
52 Week High 37.98 USD
52 Week Low 12.34 USD
50-Day Moving Average 31.95 USD
200-Day Moving Average 28.03 USD

RVNC Share Statistics

Avg. Volume (3 month) 1.27M USD
Avg. Daily Volume (10-Days) 1.34M USD
Shares Outstanding 84.04M
Float 75.76M
Short Ratio 10.63
% Held by Insiders 2.55%
% Held by Institutions 95.97%
Shares Short 15.13M
Short % of Float 20.66%
Short % of Shares Outstanding 18.01%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2022
Most Recent Quarter (mrq) March 31, 2023
Next Fiscal Year End December 31, 2023

Profitability

Profit Margin -224.64%
Operating Margin (ttm) -171.086%
Gross Margin -0.77%
EBITDA Margin -145.30%

Management Effectiveness

Return on Assets (ttm) -28.21%
Return on Equity (ttm) N/A

Income Statement

Revenue (ttm) 156.64M USD
Revenue Per Share (ttm) 2.06 USD
Quarterly Revenue Growth (yoy) 95.29%
Gross Profit (ttm) -20388000 USD
EBITDA -227592000 USD
Net Income Avi to Common (ttm) -351872992 USD
Diluted EPS (ttm) -4.53
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 273.95M USD
Total Cash Per Share (mrq) 3.26 USD
Total Debt (mrq) 435.72M USD
Total Debt/Equity (mrq) N/A
Current Ratio (mrq) 4.142
Book Value Per Share (mrq) -0.317

Cash Flow Statement

Operating Cash Flow (ttm) -201778000 USD
Levered Free Cash Flow (ttm) -107327504 USD

Profile of Revance Therapeutics

Country United States
State TN
City Nashville
Address 1222 Demonbreun Street
ZIP 37203
Phone 615 724 7755
Website https://www.revance.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 534

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids; and OPUL Relational Commerce Platform, a financial technology platform. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Q&A For Revance Therapeutics Stock

What is a current RVNC stock price?

Revance Therapeutics RVNC stock price today per share is 4.94 USD.

How to purchase Revance Therapeutics stock?

You can buy RVNC shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Revance Therapeutics?

The stock symbol or ticker of Revance Therapeutics is RVNC.

Which industry does the Revance Therapeutics company belong to?

The Revance Therapeutics industry is Biotechnology.

How many shares does Revance Therapeutics have in circulation?

The max supply of Revance Therapeutics shares is 104.21M.

What is Revance Therapeutics Price to Earnings Ratio (PE Ratio)?

Revance Therapeutics PE Ratio is now.

What was Revance Therapeutics earnings per share over the trailing 12 months (TTM)?

Revance Therapeutics EPS is -3.83 USD over the trailing 12 months.

Which sector does the Revance Therapeutics company belong to?

The Revance Therapeutics sector is Healthcare.

Revance Therapeutics RVNC included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
{{ item.name }} {{ item.symbol }} {{ item.price }} {{ item.price_usd }}
{{ item.change_pct }}
{{ item.volume }} {{ item.volume_usd }} {{ item.low }} {{ item.low_usd }} {{ item.high }} {{ item.high_usd }} {{ item.components_count }} {{ item.volume }} {{ item.volume_usd }}
NASDAQ Composite IXIC 16103.45 USD
+0.82
4.52B USD 16094.17 USD 16247.59 USD 4.52B USD
NASDAQ Biotechnology Total Retu XNBI 4654.3 USD
-0.65
4652.69 USD 4696.7 USD
Nasdaq US 700 Small Cap Index NQUS700SC 2078.81 USD
-0.4
2075.76 USD 2093.28 USD
Nasdaq AlphaDEX Multi Cap Growt NQDXUSMLTCG 2568.29 USD
+0.16
2566.7 USD 2581.47 USD
NASDAQ Biotechnology NBI 4337.34 USD
-0.65
4335.84 USD 4376.86 USD
NASDAQ HealthCare IXHC 986.88 USD
-0.25
986.44 USD 994.67 USD
NASDAQ Composite Total Return I XCMP 19565.06 USD
+0.82
19553.78 USD 19740.18 USD
NASDAQ Global Market Composite NQGM 2185.85 USD
-0.31
2177.48 USD 2204.21 USD
Stlmt ID NASDAQ Biotechnology NBX 4604.4 USD
-2.98
4555.41 USD 4917.8 USD